兴齐眼药：SQ-22031滴眼液干眼Ⅱ期临床试验完成首例受试者入组

Core Viewpoint - The company Xingqi Eye Medicine (300573) has announced the initiation of a Phase II clinical trial for its eye drop product SQ-22031, aimed at treating moderate to severe dry eye syndrome, with the first subject enrolled in the study [1] Group 1 - The clinical trial for SQ-22031 is a multicenter, randomized, double-blind, placebo-controlled study [1] - As of now, there are no approved drugs of the same category listed on the National Medical Products Administration's website [1]